首页> 美国卫生研究院文献>BMJ Open >Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance
【2h】

Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance

机译:肿瘤聚焦剂量升级的协议适应性放射治疗用于多期一期第二阶段随机对照试验(Raider)中的膀胱癌的自由基治疗:放射治疗规划和交付指导

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Daily radiotherapy delivered with radiosensitisation offers patients with muscle invasive bladder cancer (MIBC) comparable outcomes to cystectomy with functional organ preservation. Most recurrences following radiotherapy occur within the bladder. Increasing the delivered radiotherapy dose to the tumour may further improve local control. Developments in image-guided radiotherapy have allowed bladder tumour-focused ‘plan of the day’ radiotherapy delivery. We aim to test within a randomised multicentre phase II trial whether this technique will enable dose escalation with acceptable rates of toxicity.
机译:随着辐射敏感性提供的每日放疗为患有肌肉侵入性膀胱癌(MIBC)的患者提供了与功能器官保存的膀胱切除术的患者。放射治疗后的大多数复发发生在膀胱内。将递送的放疗剂量增加给肿瘤可能进一步改善局部对照。图像引导放射疗法的发展使膀胱肿瘤的重点是当天的放疗递送。我们的目标是在随机化多元期II试验中测试该技术是否能够通过可接受的毒性升级来实现剂量升级。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号